Table 1.
Clinical-pathological and radiological features of all the patients.
| Parameters | Training dataset (n=205) | P value | Testing dataset (n=87) | P value | P + value | ||
|---|---|---|---|---|---|---|---|
| Benign (n=96) | Metastases (n=109) | Benign (n=42) | Metastases (n=45) | ||||
| Age(year) | 58.0[48.0;64.0] | 61.0[55.0;66.0] | 0.002 | 53.5[44.2;64.5] | 62.0[55.0;67.0] | 0.013 | 0.653 |
| Gender | <0.001 | <0.001 | 0.826 | ||||
| Female | 57(59.4%) | 30(27.5%) | 26(61.9%) | 9(20.0%) | |||
| Male | 39(40.6%) | 79(72.5%) | 16(38.1%) | 36(80.0%) | |||
| Long diameter (cm) | 1.90[1.30;2.40] | 1.90[1.50;2.30] | 0.885 | 1.80[1.30;2.40] | 2.20[1.50;2.70] | 0.119 | 0.626 |
| Short diameter (cm) | 1.50[1.20;1.90] | 1.40[1.20;1.90] | 0.498 | 1.40[1.10;1.80] | 1.60[1.20;2.00] | 0.185 | 0.988 |
| Location | 0.293 | 0.072 | 0.834 | ||||
| Left | 65(67.7%) | 65(59.6%) | 32(76.2%) | 25(55.6%) | |||
| Right | 31(32.3%) | 44(40.4%) | 10(23.8%) | 20(44.4%) | |||
| Shape | 0.176 | 0.120 | 0.421 | ||||
| Regular | 90(93.7%) | 95(87.2%) | 39(92.9%) | 36(80.0%) | |||
| Irregular | 6(6.3%) | 14(12.8%) | 3(7.1%) | 9(20.0%) | |||
| Calcification | 0.624 | 1.000 | 1.000 | ||||
| No | 95(98.9%) | 106(97.3%) | 41(97.6%) | 44(97.8%) | |||
| Yes | 1(1.1%) | 3(2.7%) | 1(2.4%) | 1(2.2%) | |||
| Cystic degeneration/necrosis | 0.148 | 0.143 | 0.736 | ||||
| No | 84(87.5%) | 86(78.9%) | 37(88.1%) | 33(73.3%) | |||
| Yes | 12(12.5%) | 23(21.1%) | 5(11.9%) | 12(26.7%) | |||
| Plain CT value (HU) | 25.00[20.00;31.20] | 37.00[32.00;42.00] | <0.001 | 26.00[19.00;36.80] | 38.00[32.00;42.00] | <0.001 | 0.549 |
| Arterial CT value (HU) | 66.00[52.00;80.20] | 64.00[53.00;77.00] | 0.925 | 61.00[51.20;87.80] | 63.00[50.00;74.00] | 0.437 | 0.428 |
| Portal CT value (HU) | 73.50[60.00;86.20] | 74.00[61.00;87.00] | 0.611 | 77.50[63.50;95.80] | 70.00[60.00;82.00] | 0.103 | 0.959 |
| Arterial enhancement rate | 1.49[0.92;2.15] | 0.69 [0.43;1.12] | <0.001 | 1.44[1.02;2.00] | 0.57[0.43;0.81] | <0.001 | 0.431 |
| Portal enhancement rate | 1.87[1.16;2.58] | 0.89[0.71;1.39] | <0.001 | 1.82[1.27;2.86] | 0.79[0.65;1.03] | <0.001 | 0.468 |
| Peak enhancement phase | <0.001 | <0.001 | 0.639 | ||||
| Arterial phase | 23(23.9%) | 3(2.7%) | 9(21.4%) | 1(2.2%) | |||
| Portal phase | 54(56.3%) | 66(60.6%) | 29(69.1%) | 27(60.0%) | |||
| Equally enhanced | 19(19.8%) | 40(36.7%) | 4(9.5%) | 17(37.8%) | |||
| Clinical staging of lung cancer | <0.001 | <0.001 | 0.463 | ||||
| I | 15(15.6%) | 2(1.8%) | 10(23.8%) | 1(2.2%) | |||
| II | 24(25.0%) | 6(5.5%) | 6(14.3%) | 2(4.4%) | |||
| III | 33(34.4%) | 42(38.5%) | 16(38.1 %) | 16(35.6%) | |||
| IV | 24(25.0%) | 59(54.2%) | 10(23.8 %) | 26(57.8%) | |||
| Histological types of lung cancer | <0.001 | 0.006 | 0.335 | ||||
| Small cell | 7(7.3%) | 35(32.1%) | 5(11.9%) | 18(40.0%) | |||
| Non small-cell | 89(92.7%) | 74(67.9%) | 37(88.1%) | 27(60.0%) | |||
The bold values indicate the statistically significant parameters.